Amgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 winsnews2026-01-30T16:04:43+00:00January 30th, 2026|Endpoints News|
Lilly unveils $3.5B factory that will make retatrutide and other obesity drugsnews2026-01-30T16:00:33+00:00January 30th, 2026|Endpoints News|
Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeonews2026-01-30T12:00:04+00:00January 30th, 2026|Endpoints News|
Reed Jobs’ cancer biotech investment firm Yosemite eyes $350M fundnews2026-01-30T10:45:07+00:00January 30th, 2026|Endpoints News|
AstraZeneca pays $1.2B for CSPC’s long-acting obesity drugsnews2026-01-30T10:36:16+00:00January 30th, 2026|Endpoints News|
Takeda ‘anticipated’ Medicare negotiations for top seller Entyvionews2026-01-29T19:06:42+00:00January 29th, 2026|Endpoints News|
Takeda is ‘not in favor’ of MFN, CEO-designate saysnews2026-01-29T18:01:01+00:00January 29th, 2026|Endpoints News|
White House postpones planned TrumpRx launch eventnews2026-01-29T17:57:02+00:00January 29th, 2026|Endpoints News|
Sanofi vows to stay committed to vaccines as portfolio takes a hitnews2026-01-29T16:18:36+00:00January 29th, 2026|Endpoints News|
The disrupted fate of pharmacy startupsnews2026-01-29T16:14:57+00:00January 29th, 2026|Endpoints News|
